What are the next steps in management for an 80‑year‑old female with a platelet count of 677 ×10⁹/L and a positive JAK2 mutation?

Management of JAK2-Positive Essential Thrombocythemia in an 80-Year-Old

This 80-year-old woman with platelets of 677 ×10⁹/L and JAK2 mutation positivity requires immediate initiation of cytoreductive therapy with hydroxyurea plus low-dose aspirin, as she meets high-risk criteria based on age alone (>60 years). 11

Risk Stratification

Your patient is definitively high-risk for thrombotic complications based on:

• Age >60 years (she is 80)
• JAK2V617F mutation positive
• Platelet count 677 ×10⁹/L (moderately elevated but not extreme)

The 2018 European LeukemiaNet guidelines are unequivocal: patients with essential thrombocythemia (ET) should start cytoreductive treatment as soon as they reach age 60 or experience a major thrombotic/hemorrhagic event 11. Your patient meets this threshold by 20 years.

Immediate Treatment Plan

First-Line Cytoreductive Therapy

Start hydroxyurea immediately as the preferred first-line agent 11. The 2018 ELN guidelines specifically recommend hydroxyurea and recombinant interferon-α (rINFα) as first-line options, with hydroxyurea being most widely used in elderly patients. At age 80, hydroxyurea is more practical than interferon.

Dosing approach:

• Typical starting dose: 15-20 mg/kg/day (usually 500-1000 mg daily)
• Target platelet count: <400 ×10⁹/L
• Monitor complete blood count weekly initially, then every 2-4 weeks once stable

Antiplatelet Therapy

Add low-dose aspirin (75-100 mg daily) 11. The guidelines specifically state that JAK2V617F-mutated patients benefit from aspirin with reduced venous thrombosis risk and no increased bleeding risk, unlike CALR-mutated patients 11. This is particularly important in high-risk patients ≥60 years receiving cytoreductive therapy, where aspirin compensates for increased bleeding risk while preventing thrombosis.

Critical Assessment Before Starting Treatment

Rule Out Polycythemia Vera

Confirm this is ET and not PV by checking:

• Hemoglobin/hematocrit levels (should be normal in ET)
• If elevated, consider bone marrow biopsy to distinguish ET from PV, as both can present with JAK2 mutations and thrombocytosis

Assess Bleeding Risk

Given the platelet count of 677 ×10⁹/L, evaluate for acquired von Willebrand syndrome (AvWS):

• Check for mucocutaneous bleeding symptoms (epistaxis, gingival bleeding, easy bruising)
• While AvWS typically occurs with platelets >1000 ×10⁹/L, it can occur at lower counts in JAK2-mutated patients 2
• If bleeding symptoms present, consider VWF activity and antigen levels before starting aspirin

Cardiovascular Risk Factor Management

Aggressively manage all cardiovascular risk factors 33:

• Blood pressure control
• Lipid management
• Diabetes control if present
• Smoking cessation is mandatory

Monitoring Response

Use the ELN clinicohematologic response criteria 11:

Complete response:

• Platelet count ≤400 ×10⁹/L
• No disease-related symptoms
• Normal spleen size

Target timeline: Reassess at 3 months of hydroxyurea therapy

Routine monitoring:

• CBC every 2-4 weeks initially
• No need for routine JAK2 allele burden monitoring unless using interferon (which can induce molecular responses) 33

When to Consider Second-Line Therapy

Change therapy if hydroxyurea resistance/intolerance develops 113:

Resistance criteria for ET:

1. Platelet count >600 ×10⁹/L after 3 months of ≥2 g/day hydroxyurea
2. Platelet count >400 ×10⁹/L with hemoglobin <10 g/dL at any dose
3. Platelet count >400 ×10⁹/L with absolute neutrophil count <1.0 ×10⁹/L

Intolerance criteria:

• Leg ulcers or mucocutaneous manifestations
• Hydroxyurea-related fever
• GI symptoms, pneumonitis

Second-line options: Anagrelide or rINFα 11

Special Considerations for Very Elderly Patients

At age 80, intermittent busulphan may be considered as an alternative if hydroxyurea is not tolerated 1, though this is reserved for very elderly patients with short life expectancy and should not be first-line.

Critical Pitfalls to Avoid

1. Do not delay cytoreduction based on the "moderate" platelet elevation—age >60 with JAK2 mutation is sufficient indication regardless of platelet count
2. Do not withhold aspirin in JAK2-mutated patients unless active bleeding or extreme thrombocytosis (>1500 ×10⁹/L) with bleeding symptoms
3. Do not use hydroxyurea cautiously due to age—the leukemogenic concern is primarily in younger patients (<40 years) with decades of exposure 33
4. Do not start anagrelide as first-line—the 2018 ELN panel did not reach consensus on this due to insufficient evidence quality 1

Summary Algorithm

1. Confirm diagnosis: Verify ET vs PV (check hemoglobin/hematocrit)
2. Assess bleeding risk: Screen for AvWS symptoms
3. Start treatment immediately:
   • Hydroxyurea 500-1000 mg daily
   • Low-dose aspirin 75-100 mg daily
4. Optimize cardiovascular risk factors
5. Monitor CBC every 2 weeks initially
6. Reassess at 3 months for response
7. Switch to second-line only if resistance/intolerance documented